Oncology for the Inquisitive Mind

HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast cancer patients (PERSEPHONE). The advent of a new class of drugs leads to excitement, unanswered questions and boundless opportunities. With ADC (antibody-drug conjugates) making their mark on traditional chemotherapy, the landscape of everything we treat is slowly changing. Studies discussed in the episode:KATHERINEPERSEPHONEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn't stop there. It has multiple subdomains and various responses to drugs, and the complete picture is yet to be understood.This week, we explore the original wonder drug (Trastuzumab) in the early breast cancer space and its compatriot, Pertuzumab. Josh highlights the association between pathological complete responses and event-free survival/overall survival, while Michael looks at Neosphere and picks apart the data to help understand where this drug is most beneficial.Studies discussed in the episode:NEOSPHEREGEPARQUINTONOAH TRIALFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Early Breast Cancer had one of its defining moments in the 1990s, when five years of adjuvant tamoxifen reduced the recurrence risk of invasive breast cancer by 49%! These days, those types of improvements are much harder to substantiate with the effect treatments currently on the market, but there is promise. This week, on our Back to Basics episode, Michael and Josh look at the role of abemaciclib and ribociclib in the adjuvant setting in patients with high-risk early breast cancer. Both of these drugs are CDK4/6 inhibitors and have been shows to be efficacious in the metastatic hormone receptor positive status breast cancer space.This week we explore MONARCH-E and NATALEE and highlight the data and how it could impact CKD's role in this emerging landscape.Studies discussed in the episode:MONARCH-ENATALEEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Breast Cancer is complex, as are the treatment options that clinicians and patients must traverse. Stage III breast cancer has up to a 57% chance of recurring up to 20 years after diagnosis. Josh and Michael look at one of the practice-changing papers that tried to address how to manage high-risk patients. This study is called Soft and Text. It asked if adding ovarian suppression to aromatase inhibitors was better than ovarian suppression with selective estrogen receptor modulators (SERMs) to reduce the risk of recurrence in premenopausal women.Studies discussed in the episode:SOFT and TEXTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.